Core Viewpoint - Multiple companies in Hong Kong conducted share buybacks on October 3, 2025, with Tencent Holdings leading in both the number of shares repurchased and the total amount spent [1][2]. Group 1: Buyback Details - Tencent Holdings (00700) repurchased 817,000 shares for a total of 550 million [2]. - Hang Seng Bank (00011) repurchased 200,000 shares for 23.86 million [2]. - Cloud Village (N23027) repurchased 2,235,000 shares for 10.72 million [2]. - Yum China (09987) repurchased 19,000 shares for 6.28 million [2]. - Mengniu Dairy (02319) repurchased 400,000 shares for 5.90 million [2]. Group 2: Cumulative Buyback Data - Tencent Holdings has a cumulative buyback of 67.44 million shares, representing 0.734% of its total share capital [2]. - Hang Seng Bank has a cumulative buyback of 8.93 million shares, representing 0.474% of its total share capital [2]. - Cloud Village has a cumulative buyback of 8.34 million shares, representing 1.814% of its total share capital [2]. - Yum China has a cumulative buyback of 9.18 million shares, representing 2.460% of its total share capital [2]. - Mengniu Dairy has a cumulative buyback of 14.52 million shares, representing 0.371% of its total share capital [2].

希玛医疗(03309)发布公告，于2025年10月3日斥资40.08万港元回购20万股股份。 ...

Core Viewpoint - The company, Hema Medical (03309.HK), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1: Buyback Details - The company will repurchase 200,000 shares at a total cost of HKD 400,800 [1] - The buyback price range is set between HKD 1.99 and HKD 2.02 per share [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 希瑪醫療控股有限公司 呈交日期： 2025年10月3日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 03309 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 希瑪醫療控股有限公司 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03309 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 8,000,000,000 | HKD | | 0.1 HKD | | 800,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 8,000,000,000 | HKD | | 0.1 HKD | | 800,000,000 | 本月底法定/註冊股本總額： HKD 800,000,0 ...

Core Viewpoint - Hema Medical (03309) experienced a significant stock price increase of over 8%, reaching a price of 2.09 HKD following the announcement of a global licensing and collaboration agreement in the virology field for the drug encequidar with Gilead Sciences, Inc. and Hanmi Pharmaceutical Co., Ltd. [1] Group 1 - Hema Medical's stock opened more than 8% higher and was up 8.85% at the time of reporting, with a trading volume of 380,400 HKD [1] - The agreement involves Hema Medical's subsidiary granting Gilead exclusive global rights to encequidar, which Hema Medical holds outside of South Korea [1] - Hema Medical and Hanmi will provide drug supply, share technical knowledge, and participate as key partners in the project [1] Group 2 - Upon meeting certain conditions and milestones during the agreement period, Hema Medical will receive an upfront payment of 10 million USD [1] - The potential total payments Hema Medical could receive may reach up to approximately 72.5 million USD, along with royalties at a low single-digit percentage of net sales [1]

Core Viewpoint - Hema Medical (03309) experienced a significant stock price increase of over 8%, reaching HKD 2.09, following the announcement of a global licensing and collaboration agreement with Gilead Sciences, Inc. and Hanmi Pharmaceutical Co., Ltd. for the antiviral drug encequidar [1] Group 1: Company Developments - Hema Medical's subsidiary entered into a tripartite global licensing and collaboration agreement regarding the first P-glycoprotein inhibitor in the virology field [1] - The agreement grants Gilead exclusive global rights to encequidar, while Hema Medical and Hanmi will provide drug supply and share technical knowledge [1] - Hema Medical is set to receive an upfront payment of USD 10 million upon meeting certain conditions and milestones during the agreement period, with potential future payments reaching up to approximately USD 72.5 million [1] Group 2: Financial Implications - Hema Medical will also have the right to receive royalties at a low single-digit percentage on net sales of the drug [1]

Major Events - Lai Kai Pharmaceutical-B (02105) reported positive preliminary results from Phase I clinical MAD study, with LAE102 showing encouraging trends in muscle gain and fat loss [1] - Fuhong Hanlin (02696) received FDA approval for the Phase I clinical trial application of HLX13 for first-line treatment of unresectable hepatocellular carcinoma (HCC) patients [1] - Ningmeng Media (09857) has commenced filming the urban medical emotional drama "Asking Heart 2" [1] - CRRC Corporation (01766) and its subsidiaries signed significant contracts totaling approximately 54.34 billion [1] - Heng Rui Pharmaceutical (01276) received approval to conduct clinical trials for SHR-7787 injection, SHR-4849 injection, Bevacizumab injection, and Atezolizumab injection [1] - Hema Medical (03309) entered into a tripartite global licensing and collaboration agreement with Gilead and Hanmi regarding enecuidar [1] - Jinfang Pharmaceutical-B (02595) completed the enrollment of the first patient in the Phase I/II clinical trial of the molecular glue Pan RAS(ON) inhibitor GFH276 for RAS mutant cancer patients [1] - Gao Shi Medical (02407) obtained international certification for its medical device quality management system [1] Operating Performance - Shenzhen Expressway Company (00548) reported toll revenue of 114 million for the Outer Ring project in August [1] - China National Automobile (00026) announced an annual performance with a post-tax loss attributable to shareholders of 185 million HKD, a year-on-year reduction of 29.64% [1] - OKURA HOLDINGS (01655) reported an annual profit attributable to shareholders of 1.342 billion JPY, a year-on-year decrease of 34.34% [1] - Elephant Future Group (02309) disclosed an annual performance with a loss attributable to owners of approximately 314 million HKD, a year-on-year increase of 71.77% [1] - Henghe Group (00513) reported an annual performance with a loss attributable to owners of approximately 259 million HKD, a year-on-year increase of 0.7% [1]

Group 1 - The core announcement involves a tripartite global licensing and collaboration agreement between a subsidiary of Hema Medical, Gilead Sciences, Inc., and Hanmi Pharmaceutical for the first P-glycoprotein inhibitor, encequidar, in the field of virology [1] - Hema Medical and Hanmi will grant Gilead global exclusive rights to encequidar in the virology field, while also providing drug supply, sharing technical knowledge, and participating as key partners in the project [1] - Upon meeting certain conditions and milestones during the agreement period, Hema Medical will receive an upfront payment of $10 million, with potential future payments reaching up to approximately $72.5 million, along with a low single-digit royalty on net sales [1] Group 2 - Hema Medical is primarily engaged in the development of innovative drugs in the oncology field and is currently researching oral formulations of encequidar [2] - The company is preparing to initiate a Phase 3 global clinical study for the treatment of metastatic breast cancer using oral paclitaxel combined with encequidar, aiming to replace intravenous administration of paclitaxel in chemotherapy [2] - The clinical study is planned to commence by the end of 2025 across multiple centers in the United States, Hong Kong, and New Zealand [2]

Group 1 - The core point of the news is that Hema Medical (希华医药) has entered into a global licensing and collaboration agreement with Gilead Sciences and Hanmi Pharmaceutical for the P-glycoprotein inhibitor encequidar, which Hema Medical holds exclusive global rights outside of South Korea [1] - Under the agreement, Hema Medical and Hanmi will grant Gilead exclusive global rights to encequidar in the field of virology, and they will also provide drug supply and share technical knowledge [1] - Hema Medical is set to receive an initial payment of $10 million, with potential future payments reaching up to approximately $72.5 million, along with a low single-digit royalty on net sales [1] Group 2 - Hema Medical is primarily focused on innovative drug development in the oncology field and is currently researching oral formulations of encequidar [2] - The company is preparing to initiate a Phase 3 global clinical study for the treatment of metastatic breast cancer using oral paclitaxel combined with encequidar, which aims to replace intravenous administration of paclitaxel in chemotherapy [2] - The clinical study is planned to commence by the end of 2025 across multiple centers in the United States, Hong Kong, and New Zealand [2]